ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
Cell-free circulating tumor DNA (ctDNA) is synthesized by tumor cells, including metastatic tumors, and circulates in the bloodstream. Evidence suggests that ctDNA is a potential predictive and prognostic biomarker for colorectal cancer (CRC), but its predictive efficacy in detecting CRC liver metas...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-05-01
|
| Series: | Open Life Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/biol-2022-0615 |
| _version_ | 1797814200840486912 |
|---|---|
| author | Wang Da Zhao Penglai Lu Tingting Ren Jingyao Zhu Lihui Han Xiaoyong Zhang Guangming Dong Xiaohua Ma Haizhong Yu Miao Cai Hui |
| author_facet | Wang Da Zhao Penglai Lu Tingting Ren Jingyao Zhu Lihui Han Xiaoyong Zhang Guangming Dong Xiaohua Ma Haizhong Yu Miao Cai Hui |
| author_sort | Wang Da |
| collection | DOAJ |
| description | Cell-free circulating tumor DNA (ctDNA) is synthesized by tumor cells, including metastatic tumors, and circulates in the bloodstream. Evidence suggests that ctDNA is a potential predictive and prognostic biomarker for colorectal cancer (CRC), but its predictive efficacy in detecting CRC liver metastasis (CLM) remains unclear. Additionally, its utility in the clinical setting needs further investigation. We conducted a meta-analysis to determine the utility of ctDNA as a biomarker for predicting the prognosis of CLM and investigate the relationship between CLM and ctDNA positivity. A literature search was performed in electronic databases to identify relevant studies published up to March 19, 2022. We retrieved data on overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) for both ctDNA-positive and ctDNA-negative colorectal liver metastasis (CLM) patients from the selected articles. Hazard ratios (HRs) were also calculated for these survival outcomes analysis was also performed. The stability of the combined meta-analysis was verified by sensitivity analysis and publication bias evaluation. Ten trials were included, and 615 patients were evaluated. In patients with CLM, pooled HRs revealed a substantial link between ctDNA positivity and RFS/DFS. Subgroup analysis revealed that ctDNA had a prospective detection value. Sensitivity analysis and publication bias evaluation indicated stable results. Although the results on pooled HR for OS suggested that ctDNA-positive patients had a shorter survival time, their pooled HRs had a relatively evident heterogeneity, and sensitivity analysis and publication bias evaluation indicated that pooled HRs were extremely unstable. In conclusion, our results demonstrate that ctDNA appears to be a prognostic biomarker for resectable CLM patients. |
| first_indexed | 2024-03-13T08:04:05Z |
| format | Article |
| id | doaj.art-4a84282d996b4436835676d7fda83f88 |
| institution | Directory Open Access Journal |
| issn | 2391-5412 |
| language | English |
| last_indexed | 2024-03-13T08:04:05Z |
| publishDate | 2023-05-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Life Sciences |
| spelling | doaj.art-4a84282d996b4436835676d7fda83f882023-06-01T09:42:08ZengDe GruyterOpen Life Sciences2391-54122023-05-011812094910.1515/biol-2022-0615ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysisWang Da0Zhao Penglai1Lu Tingting2Ren Jingyao3Zhu Lihui4Han Xiaoyong5Zhang Guangming6Dong Xiaohua7Ma Haizhong8Yu Miao9Cai Hui10School of Medicine Jiangsu University, Zhenjiang, 212000, ChinaGeneral Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, 730000, ChinaInstitution of Clinical Research and Evidence Based Medicine, Gansu Provincial Hospital, Lanzhou, 730000, ChinaKey Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou, 730000, ChinaKey Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou, 730000, ChinaKey Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou, 730000, ChinaGeneral Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, 730000, ChinaGeneral Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, 730000, ChinaGeneral Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, 730000, ChinaGeneral Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, 730000, ChinaSchool of Medicine Jiangsu University, Zhenjiang, 212000, ChinaCell-free circulating tumor DNA (ctDNA) is synthesized by tumor cells, including metastatic tumors, and circulates in the bloodstream. Evidence suggests that ctDNA is a potential predictive and prognostic biomarker for colorectal cancer (CRC), but its predictive efficacy in detecting CRC liver metastasis (CLM) remains unclear. Additionally, its utility in the clinical setting needs further investigation. We conducted a meta-analysis to determine the utility of ctDNA as a biomarker for predicting the prognosis of CLM and investigate the relationship between CLM and ctDNA positivity. A literature search was performed in electronic databases to identify relevant studies published up to March 19, 2022. We retrieved data on overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) for both ctDNA-positive and ctDNA-negative colorectal liver metastasis (CLM) patients from the selected articles. Hazard ratios (HRs) were also calculated for these survival outcomes analysis was also performed. The stability of the combined meta-analysis was verified by sensitivity analysis and publication bias evaluation. Ten trials were included, and 615 patients were evaluated. In patients with CLM, pooled HRs revealed a substantial link between ctDNA positivity and RFS/DFS. Subgroup analysis revealed that ctDNA had a prospective detection value. Sensitivity analysis and publication bias evaluation indicated stable results. Although the results on pooled HR for OS suggested that ctDNA-positive patients had a shorter survival time, their pooled HRs had a relatively evident heterogeneity, and sensitivity analysis and publication bias evaluation indicated that pooled HRs were extremely unstable. In conclusion, our results demonstrate that ctDNA appears to be a prognostic biomarker for resectable CLM patients.https://doi.org/10.1515/biol-2022-0615ctdnacolorectal cancer liver metastasismeta-analysisprognostic biomarker |
| spellingShingle | Wang Da Zhao Penglai Lu Tingting Ren Jingyao Zhu Lihui Han Xiaoyong Zhang Guangming Dong Xiaohua Ma Haizhong Yu Miao Cai Hui ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis Open Life Sciences ctdna colorectal cancer liver metastasis meta-analysis prognostic biomarker |
| title | ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis |
| title_full | ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis |
| title_fullStr | ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis |
| title_full_unstemmed | ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis |
| title_short | ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis |
| title_sort | ctdna as a prognostic biomarker in resectable clm systematic review and meta analysis |
| topic | ctdna colorectal cancer liver metastasis meta-analysis prognostic biomarker |
| url | https://doi.org/10.1515/biol-2022-0615 |
| work_keys_str_mv | AT wangda ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT zhaopenglai ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT lutingting ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT renjingyao ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT zhulihui ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT hanxiaoyong ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT zhangguangming ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT dongxiaohua ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT mahaizhong ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT yumiao ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis AT caihui ctdnaasaprognosticbiomarkerinresectableclmsystematicreviewandmetaanalysis |